.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,057,307

« Back to Dashboard

Claims for Patent: 6,057,307

Title: Use of mometasone furoate for treating airway passage and lung diseases
Abstract:The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
Inventor(s): Sequeira; Joel A. (Scotch Plains, NJ), Cuss; Francis M. (Basking Ridge, NJ), Nolop; Keith B. (Millburn, NJ), Chaudry; Imtiaz A. (North Caldwell, NJ), Nagabhushan; Nagamani (Parsippany, NJ), Patrick; James E. (Belle Meade, NJ), Cayen; Mitchell (Bedminster, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:09/259,721
Patent Claims: 1. A method of treating a corticosteroid-responsive disease of the lower airway passages or lungs, which comprises administering as initial or maintenance therapy to the surfaces of said lower airway passages or lungs, at least once daily, a substantially non-systemically bioavailable amount of aerosolized particles of mometasone furoate effective for treating said disease.

2. The method of claim 1, wherein the disease comprises an allergic or inflammatory disease.

3. The method of claim 1, wherein the disease comprises asthma.

4. The method of claim 1, wherein the disease comprises chronic obstructive pulmonary disease.

5. The method of claim 1, wherein the disease comprises a granulomatous disease.

6. The method of claim 1, wherein the disease comprises a non-malignant proliferative and/or inflammatory disease.

7. The method of claim 1, wherein the disease comprises idiopathic pulmonary fibrosis.

8. The method of claim 1, wherein the disease comprises bronchopulmonary dysphasia.

9. The method of claim 1, wherein the disease comprises hypersensitivity pneumonitis.

10. The method of claim 1, wherein the daily amount of mometasone furoate administered is about 10 to about 2000 micrograms.

11. The method of claim 1, wherein the daily amount of mometasone furoate administered is about 50 to about 1000 micrograms.

12. The method of claim 1, wherein the mometasone furoate is administered once or twice daily.

13. The method of claim 1, wherein the mometasone furoate is administered once daily.

14. The method of claim 1, wherein the mometasone furoate is administered by oral inhalation.

15. The method of claim 1, wherein the mometasone furoate is delivered by a pressurized aerosol metered dose inhaler.

16. The method of claim 1, wherein the mometasone furoate is delivered by a dry powder inhaler.

17. A method of treating a corticosteroid-responsive allergic or inflammatory disease of the lower airway passages or lungs, which comprises administering as initial or maintenance therapy to the surfaces of said lower airway passages or lungs, once or twice daily, a substantially non-systemically bioavailable amount of aerosolized particles of mometasone furoate effective for treating said disease.

18. The method of claim 17, wherein the disease comprises at least one disorder selected from the group consisting of asthma, chronic obstructive pulmonary disease, a granulomatous disease, a non-malignant proliferative and/or inflammatory disease, idiopathic pulmonary fibrosis, bronchopulmonary dysphasia and hypersensitivity pneumonitis.

19. The method of claim 17, wherein the daily amount of mometasone furoate administered is about 10 to about 2000 micrograms.

20. The method of claim 17, wherein the daily amount of mometasone furoate administered is about 50 to about 1000 micrograms.

21. The method of claim 17, wherein the mometasone furoate is administered once daily.

22. The method of claim 17, wherein the mometasone furoate is administered by oral inhalation.

23. The method of claim 17, wherein the mometasone furoate is delivered by a pressurized aerosol metered dose inhaler.

24. The method of claim 17, wherein the mometasone furoate is delivered by a dry powder inhaler.

25. A dosage form for treating a corticosteroid-responsive disease of the lower airway passages or lungs, said dosage form comprising a device which contains and can deliver to the surfaces of said airway passages or lungs at least one daily initial or maintenance therapy dose comprising about 10 to about 2000 micrograms of aerosolized particles of mometasone furoate.

26. The dosage form of claim 25, which contains and can deliver a plurality of doses of mometasone furoate.

27. The dosage form of claim 25, which comprises a pressurized aerosol metered dose inhaler.

28. The dosage form of claim 25, which comprises a dry powder inhaler.

29. The dosage form of claim 25, wherein the mometasone furoate is admixed with lactose.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc